MedBioinformatics Announces Participation in IHI JU VICT3R Initiative to Revolutionize Nonclinical Drug and Chemical Safety Evaluation with Virtual Controls

News September 16, 2024

[Barcelona, Spain, September 16, 2024] — MedBioinformatics today announced its involvement in the VICT3R initiative, a groundbreaking initiative aimed at transforming nonclinical drug and chemical safety evaluation. VICT3R is a public-private partnership supported by the Innovative Health Initiative Joint Undertaking (IHI JU), set to significantly reduce the number of animals used in experimental studies. The […]

Genetics In Drug Discovery: The Key To Clinical Trial Success?

Article August 28, 2024

By leveraging human genetics to identify drug targets with a proven link to disease mechanisms, the probability of clinical trial success greatly increases [1].  Only 10% of drugs that enter phase 1 clinical trials eventually make it to market [2], primarily due to issues related to efficacy or safety that arise later on. These frequent […]

DISGENET Academic License: Eligibility, Application & Free Access

Product August 2, 2024

DISGENET is the most extensive and reliable gene-disease association network, providing the latest and most relevant data in the field. It was created by MedBioinformatics, and as an academic or not-for-profit researcher, you can access DISGENET’s core biomedical data at no cost. For deeper insights, we offer additional options utilizing state-of-the-art NLP technology. In this […]